Waning effectiveness of SARS-CoV-2 mRNA vaccines in older adults: a rapid review

Abstract

The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies have recently recommended a booster dose of COVID-19 vaccines for specific vulnerable groups including adults 65 years and older. There is limited evidence whether vaccine effectiveness (VE) in older adults decreases over time, especially against severe COVID-19. We performed a rapid review of published studies available through 4 November 2021 that provide effectiveness data on messenger RNA (mRNA) vaccines approved/licensed in the United States and identified eight eligible studies which evaluated VE in older adults. There is evidence of a decline in VE against both severe acute respiratory syndrome coronavirus 2 infection and severe COVID-19 in older adults among studies which analyzed data up to July–October 2021. Our findings suggest that VE diminishes in older adults, which supports the current recommendation for a booster dose in this population.

Keywords

• vaccine
• covid-19
• waning
• older adults
• effectiveness